SOURCE: StockCall

StockCall

August 05, 2011 08:35 ET

Equity Research on Forest Laboratories Inc. and Endo Pharmaceuticals Holdings Inc. - Drug Manufacturers - Other Look to New Drugs to Combat Expirations

JOHANNESBURG, SOUTH AFRICA--(Marketwire - Aug 5, 2011) - www.stockcall.com/ offers investors comprehensive research on the Drug Manufacturers - Other industry and has completed analytical research on Forest Laboratories Inc. (NYSE: FRX) and Endo Pharmaceuticals Holdings Inc. (NASDAQ: ENDP). Register with us today at www.stockcall.com/ to have free access to these researches.

The Drug Manufacturers - Other sector, like the rest of the pharmaceutical world, has a major cause for concern with the coming patent expirations during the next few years. As many big-revenue medications come off patent protection and become available for generic drug makers to copy and sell them, companies will have to find new ways to make up for lost revenue. Register now at https://stockcall.com/development/stockcall/page.php?name=register.html to have free access to our reports on the Drug Manufacturers - Other industry.

www.stockcall.com/ is an online platform where investors doing their due-diligence on the Drug Manufacturers - Other industry can have easy and free access to our analyst research and opinions on Forest Laboratories Inc. and Endo Pharmaceuticals Holdings Inc.; investors and shareholders of these companies can simply register for a complimentary membership at https://stockcall.com/development/stockcall/page.php?name=register.html.

Forest Laboratories Inc., for example, is optimistic about the expansion of sales for new drugs to help offset the loss of Lexapro's patent which expires in March 2012. The company which is currently embroiled in a conflict with Carl Icahn over positions on its board has gone as far as making new acquisitions to help bolster its drug portfolio. Forest Laboratories Inc. research report is accessible for free by registering today at www.stockcall.com/FRX050811.pdf.

This trend towards acquiring new drugs is common throughout the sector. With a new drug from BioSante Pharmaceuticals out to help improve low libido for women, many companies in the pharmaceutical world are interested in working a deal with the company. Endo Pharmaceuticals Holdings Inc. is thought to be one of the companies interested in the potentially $4 billion per year market. Endo Pharmaceuticals Holdings Inc. research report is available for free by signing up now at www.stockcall.com/ENDP050811.pdf.

Visit www.stockcall.com/ to see how companies in this industry have grown over the past years and how they are expected to perform in the future.

About StockCall.com
StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines.

Contact Information